KCM
AXSM icon

Kennedy Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Kennedy Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.79M Sell
35,909
-866
-2% -$188K 0.16% 221
2026
Q1 		$6.22M Sell
36,775
-2,359
-6% -$407K 0.13% 243
2025
Q4 		$7.15M Buy
39,134
+360
+0.9% +$50.3K 0.15% 219
2025
Q3 		$4.71M Buy
38,774
+10,819
+39% +$1.22M 0.1% 307
2025
Q2 		$2.92M Buy
27,955
+22,133
+380% +$2.34M 0.07% 380
2025
Q1 		$679K Sell
5,822
-32,119
-85% -$3.66M 0.02% 558
2024
Q4 		$3.21M Buy
37,941
+18,510
+95% +$1.7M 0.07% 413
2024
Q3 		$1.75M Sell
19,431
-1,184
-6% -$103K 0.04% 535
2024
Q2 		$1.66M Buy
20,615
+1,132
+6% +$83.8K 0.04% 533
2024
Q1 		$1.55M Buy
19,483
+6,136
+46% +$515K 0.03% 563
2023
Q4 		$1.06M Buy
13,347
+1,255
+10% +$83.9K 0.02% 580
2023
Q3 		$845K Buy
12,092
+2,354
+24% +$176K 0.02% 580
2023
Q2 		$700K Buy
+9,738
New +$718K 0.02% 580

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Kennedy Capital Management's AXSM Position: Q2 2026 in Review

Kennedy Capital Management reduced its Axsome Therapeutics (AXSM) stake by 2.4% in Q2 2026, selling an estimated $188K and leaving 35,909 shares worth $8.79M. The position accounts for 0.16% of the portfolio, ranked #221.

Kennedy Capital Management first reported a position in AXSM in Q2 2023 and has held it in 13 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Kennedy Capital Management held 35,909 shares of Axsome Therapeutics worth $8.79M as of Q2 2026.
  • Kennedy Capital Management sold 866 Axsome Therapeutics shares in Q2 2026, an estimated $188K.
  • Axsome Therapeutics made up 0.16% of Kennedy Capital Management's portfolio in Q2 2026, its #221 holding.
  • Kennedy Capital Management first reported a position in Axsome Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.